152 related articles for article (PubMed ID: 26137805)
21. Increased AT(2)R protein expression but not increased apoptosis during cardioprotection induced by AT(1)R blockade.
Moudgil R; Musat-Marcu S; Xu Y; Kumar D; Jugdutt BI
Can J Cardiol; 2002 Oct; 18(10):1107-16. PubMed ID: 12420045
[TBL] [Abstract][Full Text] [Related]
22. Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
Siragy HM; El-Kersh MA; De Gasparo M; Webb RL; Carey RM
J Hypertens; 2002 Jun; 20(6):1157-63. PubMed ID: 12023686
[TBL] [Abstract][Full Text] [Related]
23. Effect of valsartan on the expression of angiotensin II receptors in the lung of chronic antigen exposure rats.
Wang T; Yin KS; Liu KY; Lu GJ; Li YH; Chen JD
Chin Med J (Engl); 2008 Nov; 121(22):2312-9. PubMed ID: 19080339
[TBL] [Abstract][Full Text] [Related]
24. Increased AT2R protein expression but not increased apoptosis during cardioprotection induced by AT1R blockade.
Moudgil R; Musat-Marcu S; Xu Y; Kumar D; Jugdutt BI
Can J Cardiol; 2002 Aug; 18(8):873-83. PubMed ID: 12215750
[TBL] [Abstract][Full Text] [Related]
25. Opposite effects of angiotensin AT1 and AT2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts.
Ford WR; Clanachan AS; Jugdutt BI
Circulation; 1996 Dec; 94(12):3087-9. PubMed ID: 8989113
[TBL] [Abstract][Full Text] [Related]
26. Valsartan attenuates oxidative stress and NF-κB activation and reduces myocardial apoptosis after ischemia and reperfusion.
Wu B; Lin R; Dai R; Chen C; Wu H; Hong M
Eur J Pharmacol; 2013 Apr; 705(1-3):140-7. PubMed ID: 23499691
[TBL] [Abstract][Full Text] [Related]
27. Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity.
Siragy HM; Huang J
Exp Physiol; 2008 May; 93(5):709-14. PubMed ID: 18192338
[TBL] [Abstract][Full Text] [Related]
28. Cardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicity.
Bozcali E; Dedeoglu DB; Karpuz V; Suzer O; Karpuz H
Acta Cardiol; 2012 Feb; 67(1):87-96. PubMed ID: 22455094
[TBL] [Abstract][Full Text] [Related]
29. Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
Thai H; Guarraia D; Johnson N; Goldman S; Gaballa MA
J Cardiovasc Pharmacol; 2007 Dec; 50(6):703-7. PubMed ID: 18091589
[TBL] [Abstract][Full Text] [Related]
30. Critical role of angiotensin II type 2 receptors in the control of mitochondrial and cardiac function in angiotensin II-preconditioned rat hearts.
Nuñez RE; Javadov S; Escobales N
Pflugers Arch; 2018 Sep; 470(9):1391-1403. PubMed ID: 29748710
[TBL] [Abstract][Full Text] [Related]
31. Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade.
Sawicki G; Menon V; Jugdutt BI
J Card Fail; 2004 Oct; 10(5):442-9. PubMed ID: 15470656
[TBL] [Abstract][Full Text] [Related]
32. Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats.
Chan P; Liu IM; Tzeng TF; Yang TL; Cheng JT
Diabetes Obes Metab; 2007 Jan; 9(1):39-49. PubMed ID: 17199717
[TBL] [Abstract][Full Text] [Related]
33. Effects of simvastatin on cardiohemodynamic responses to ischemia-reperfusion in isolated rat hearts.
Zheng X; Hu SJ
Heart Vessels; 2006 Mar; 21(2):116-23. PubMed ID: 16550313
[TBL] [Abstract][Full Text] [Related]
34. Valsartan decreases neointimal hyperplasia in balloon-injured rat aortic arteries by upregulating HO-1 and inhibiting angiotensin II type 1 receptor.
Li Y; Wang Q; Xu Q; Cai S; Zhou J; Ren B; Sun T; Liu X; Yu H
Life Sci; 2014 Aug; 110(2):70-6. PubMed ID: 25014676
[TBL] [Abstract][Full Text] [Related]
35. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
36. AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Clair MJ; Krombach RS; Hendrick JW; Houck WV; Hebbar L; Kribbs SB; Rios G; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
J Card Fail; 1998 Dec; 4(4):311-23. PubMed ID: 9924853
[TBL] [Abstract][Full Text] [Related]
37. Release of preformed Ang II from myocytes mediates angiotensinogen and ET-1 gene overexpression in vivo via AT1 receptor.
Amedeo Modesti P; Zecchi-Orlandini S; Vanni S; Polidori G; Bertolozzi I; Perna AM; Formigli L; Cecioni I; Coppo M; Boddi M; Serneri GG
J Mol Cell Cardiol; 2002 Nov; 34(11):1491-500. PubMed ID: 12431448
[TBL] [Abstract][Full Text] [Related]
38. Haemodynamic effects of valsartan in acute renal ischaemia/reperfusion injury.
Lopau K; Hefner L; Bender G; Heidbreder E; Wanner C
Nephrol Dial Transplant; 2001 Aug; 16(8):1592-7. PubMed ID: 11477160
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis.
Tachikawa H; Kodama M; Hui L; Yoshida T; Hayashi M; Abe S; Kashimura T; Kato K; Hanawa H; Watanabe K; Nakazawa M; Aizawa Y
J Cardiovasc Pharmacol; 2003 Jan; 41 Suppl 1():S105-10. PubMed ID: 12688405
[TBL] [Abstract][Full Text] [Related]
40. [Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan].
Zhong M; Zhang Y; Miao Y; Li L; Gong HP; Ma X; Sun H; Zhang W
Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(4):232-6. PubMed ID: 16677501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
